logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
H

Hiroji Iwata

Nagoya City University
H指数:89
被引数:5.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Trastuzumab deruxtecan rechallenge in HER2-positive metastatic breast cancer: EN-SEMBLE

曲妥珠单抗德鲁替康再次治疗在HER2阳性转移性乳腺癌中的应用：EN-SEMBLE

Breast
IF7.9
2026-08-010
PRE
Nozawa, Kazuki; Iwata, Hiroji; Mukohara, Toru; Taira, Tetsuhiko; Yoshimura, Akiyo; Nagai, Shigenori E.; Hashimoto, Jun; Matsuura, Kazuo; Mizuno, Toshiro; Shinden, Yoshiaki; Yamamoto, Mitsugu; Takano, Toshimi; Wakahara, Makoto; Terakawa, Hirofumi; Yamanaka, Takashi; Kojima, Yasuyuki; Nakayama, Takahiro; Hirakawa, Yuji; Shiosakai, Kazuhito; Tsurutani, Junji
SERENA-6 visual patient-reported outcomes and safety: camizestrant for emerging ESR1m advanced breast cancer during first-line endocrine-based therapy

SERENA-6视觉患者报告结局与安全性：卡米昔司rant用于新发ESR1m晚期乳腺癌的一线内分泌治疗

Oncologist
IF4.2
2026-07-240
OAAI
Adam Brufsky, MD; Yeon Hee Park, MD; François-Clément Bidard, MD; Erica L Mayer, MD; Wolfgang Janni, MD; Cynthia Ma, MD; Massimo Cristofanilli, MD; Giampaolo Bianchini, MD; Hiroji Iwata, MD; Peter A Fasching, MD; Zbigniew Nowecki, MD; Javier Pascual, MD; Shin-Cheh Chen, MD; Lionel Moreau, MD; Manuel Ruiz-Borrego, MD; Ayelet Shai, MD; Nuri Karadurmus, MD; Kyung Hae Jung, MD; Yuichiro Kikawa, MD; Richard D Baird, MD; Ranya Habash, MD; Rebecca Sugarman, MSc; Steven Fox, MSc; Manuel Selvi Miralles, MD; Cynthia Huang Bartlett, MD; Nicholas Turner, MD; null
Prognosis of ER-positive, HER2-negative postmenopausal early breast cancer patients based on response to neoadjuvant endocrine therapy and multigene assay results: findings from the NEOS trial

基于新辅助内分泌治疗反应和多基因检测结果的ER阳性、HER2阴性绝经后早期乳腺癌患者预后：NEOS试验结果

Breast Cancer
IF2.9
2026-06-180
OAAI
Hiroji Iwata; Norikazu Masuda; Yutaka Yamamoto; Tomomi Fujisawa; Tatsuya Toyama; Masahiro Kashiwaba; Shoichiro Ohtani; Naruto Taira; Takehiko Sakai; Yoshie Hasegawa; Rikiya Nakamura; Takuhiro Yamaguchi; Kentaro Sakamaki; Christy A. Russell; Naoko Sugiyama
Primary tumour resection reduces the risk of major local morbidity in de novo stage IV breast cancer: secondary data analysis from the JCOG1017 randomized controlled trial

原发肿瘤切除可降低新诊断IV期乳腺癌的主要局部并发症风险：来自JCOG1017随机对照试验的二次数据分析

bjs
IF0
2026-05-010
PRE
Makoto Ishitobi; Kiyo Tanaka; Akihiko Shimomura; Takashi Yamanaka; Takahiro Tsukioki; Hiroji Iwata; Fumikata Hara; Tomomi Fujisawa; Keita Sasaki; Riku Kajikawa; Takehiko Sakai; Yasuaki Sagara; Hideo Shigematsu; Yukinori Ozaki; Kazuki Nozawa; Kazuki Sudo; Yoichi Naito; Kaori Terata; Toshiyuki Ishiba; Haruhiko Fukuda; Tadahiko Shien
Capivasertib plus paclitaxel as first-line treatment for metastatic triple-negative breast cancer: Results from the randomised, global phase III CAPItello-290 trial

Capivasertib 联合紫杉醇作为转移性三阴性乳腺癌的一线治疗：来自随机、全球性III期CAPItello-290试验的结果

Annals of Oncology
IF65.4
2025-12-190
PRE
P.S. Schmid; H.L. McArthur; J. Cortés; B. Xu; F. Cardoso; M. Casalnuovo; U. Demirci; R. Freitas-Junior; J. Ghosh; R. Hegg; H. Iwata; I. Karnaukhov; Y.L. Chuken; M. Nechaeva; M.E. Robson; R. Villalobos-Valencia; T. Yamashita; B. Zurawski; E.C. de Bruin; L. Grinsted
Pooled analysis by best confirmed response to trastuzumab deruxtecan and related biomarkers in patients with HER2-positive metastatic breast cancer from DESTINY-Breast01, DESTINY-Breast02, and DESTINY-Breast03

来自DESTINY-Breast01，DESTINY-Breast02和DESTINY-Breast03的HER2-positive转移性乳腺癌患者对曲妥珠单抗deruxtecan和相关生物标志物的最佳确认反应的汇总分析

Annals of Oncology
IF65.4
2025-11-180
PRE
C. Saura; J. Cortés; S. Modi; S.-B. Kim; E. Hamilton; S.A. Hurvitz; I.E. Krop; G. Curigliano; H. Iwata; S.-A. Im; P. Herbolsheimer; M. Karnoub; A. Boran; Y. Kuwahara; A. Egorov; F. André
Association between adjuvant chemotherapy and outcomes in resected locoregional recurrence of hormone receptor-positive HER2-negative breast cancer: a multi-institutional retrospective study

激素受体阳性HER2阴性乳腺癌局部区域复发切除术后辅助化疗与预后的关系：一项多中心回顾性研究

ESMO Open
IF8.3
2025-11-070
OAAI
Y. Ozaki; E. Tokuda; Y. Sagara; F. Hara; S. Sasada; M. Sawaki; C. Kanbayashi; T. Yamanaka; T. Onishi; Y. Fujiki; A. Suto; Y. Takahashi; E. Tokunaga; T. Aruga; R. Nakamura; T. Fujisawa; S. Saji; H. Iwata; T. Shien
Patient-reported outcomes in the SERENA-6 trial of camizestrant plus CDK4/6 inhibitor in patients with advanced breast cancer and emergent ESR1 mutations during first-line endocrine-based therapy

SERENA-6试验中，卡米泽斯特ант联合CDK4/6抑制剂治疗在初次内分泌治疗期间出现ESR1突变的晚期乳腺癌患者的患者报告结局。

Annals of Oncology
IF65.4
2025-10-200
OAAI
E.L. Mayer; F.-C. Bidard; Y.H. Park; W. Janni; C. Ma; M. Cristofanilli; H. Iwata; G. Bianchini; K. Kalinsky; S. Chia; A. Brufsky; P.A. Fasching; Z. Nowecki; S.-C. Chen; J. Pascual; L. Moreau; M. Ruiz-Borrego; A. Shai; N. Karadurmus; J.H. Sohn; Y. Zhu; I. Leddin; M.S. Miralles; C.H. Bartlett; N. Turner
Effectiveness of post-trastuzumab deruxtecan treatments and incidence of interstitial lung disease in HER2-positive metastatic breast cancer: a real-world, observational cohort study☆

曲妥珠单抗德鲁克替康治疗后疗效及间质性肺病发生率：一项真实世界、观察性队列研究

ESMO Open
IF8.3
2025-07-250
OAAI
K. Nozawa; H. Iwata; T. Mukohara; T. Taira; A. Yoshimura; S.E. Nagai; J. Hashimoto; K. Matsuura; T. Mizuno; Y. Shinden; M. Yamamoto; T. Takano; M. Wakahara; H. Terakawa; T. Yamanaka; Y. Kojima; T. Nakayama; Y. Hirakawa; K. Kuge; A. Tanabe; J. Tsurutani
Primary tumour resection plus systemic therapy versus systemic therapy alone in metastatic breast cancer (JCOG1017, PRIM-BC): a randomised clinical trial

转移性乳腺癌原发肿瘤切除加全身治疗与单纯全身治疗的比较 (JCOG1017，prim-bc): 一项随机临床试验

British Journal of Cancer
IF6.8
2025-07-040
OAAI
Tadahiko Shien; Fumikata Hara; Kenjiro Aogi; Yasuhiro Yanagida; Michiko Tsuneizumi; Naohito Yamamoto; Hiroshi Matsumoto; Akihiko Suto; Kenichi Watanabe; Michiko Harao; Chizuko Kanbayashi; Mitsuya Itoh; Takayuki Kadoya; Keisei Anan; Shigeto Maeda; Keita Sasaki; Gakuto Ogawa; Shigehira Saji; Haruhiko Fukuda; Hiroji Iwata
Outcomes in stage IIA versus stage IIB/III in the PALLAS trial [ABCSG-42/AFT-05/PrE0109/BIG-14-13])
BREAST CANCER RESEARCH
IF5.6
2025-01-230
OAAI
Demichele, A.; Dueck, A. C.; Hlauschek, D.; Martin, M.; Burstein, H.; Pfeiler, G.; Zdenkowski, N.; Wolff, A.; Bellet-Ezquerra, M.; Winer, E.; Balic, M.; Miller, K.; Colleoni, M.; Lake, D.; Rubovsky, G.; Cameron, D.; Balko, J.; Singer, C. F.; Nowecki, Z.; Iwata, H.; Wolmark, N.; Parraga, K. A.; Rugo, H.; Steger, G. G.; Traina, T.; Werutsky, G.; Czajkowska, D.; Metzger, O.; El-Abed, S.; Theall, K. P.; Lu, R. D.; O'Brien, P.; Fesl, C.; Mayer, E.; Gnant, M.
Exploring locoregional treatment reporting in neoadjuvant systemic breast cancer treatment studies: A systematic review☆
EJSO
IF2.9
2024-10-010
PRE
Jiang, Michael; Avery, Kerry; Ahmed, Rosina; de Boniface, Jana; Chatterjee, Sanjoy; Dodwell, David; Dubsky, Peter; Finestone, Sandy; Iwata, Hiroji; Lee, Han-Byoel; MacKenzie, Mairead; Meyn, Anne; Poulakaki, Fiorita; Richardson, Andrea L.; Sepulveda, Karla; Spillane, Andrew; Thompson, Alastair M.; Werutsky, Gustavo; Wright, Jean L.; Zdenkowski, Nicholas; Cowan, Katherine; McIntosh, Stuart A.; Potter, Shelley
Efficacy of antibody drug conjugate (ADC) by mRNA expression of targeted genes in advanced solid tumors: SCRUM-Japan MONSTAR-SCREEN-2

抗体药物偶联物（ADC）在晚期实体瘤中的疗效：基于靶向基因的mRNA表达，SCRUM-Japan MONSTAR-SCREEN-2

ANNALS OF ONCOLOGY
IF65.4
2024-09-010
PRE
Fujisawa, T.; Nakamura, Y.; Sakamoto, N.; Hashimoto, T.; Nagamine, M.; Kuwata, T.; Ishii, G.; Yamashita, R.; Morizane, C.; Nonomura, N.; Iwata, H.; Okano, S.; Watari, H.; Namikawa, K.; Shibuki, T.; Imai-Sumida, M.; Bando, H.; Radovich, M.; Sledge, G.; Yoshino, T.
Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study

Capivasertib和fulvestrant治疗激素受体阳性晚期乳腺癌患者: III期CAPItello-291研究中常见不良事件的特征、时程和处理

ESMO OPEN
IF8.3
2024-09-013
OAAI
Rugo, H. S.; Oliveira, M.; Howell, S. J.; Dalenc, F.; Cortes, J.; Gomez, H. L.; Hu, X.; Jhaveri, K. L.; Krivorotko, P.; Loibl, S.; Murillo, S. Morales; Nowecki, Z.; Okera, M.; Park, Y. H.; Sohn, J.; Toi, M.; Iwata, H.; Yousef, S.; Zhukova, L.; Logan, J.; Twomey, K.; Khatun, M.; D'Cruz, C. M.; Turner, N. C.

研究方向

暂未获取到该数据
N
Norikazu Masuda
H 指数:64论文数:697被引数:2.9万
M
Masataka Sawaki
H 指数:25论文数:227被引数:2,192
S
Shigehira Saji
H 指数:47论文数:422被引数:1.1万
M
Masaya Hattori
H 指数:30论文数:233被引数:9,499
M
Masakazu Toi
H 指数:2论文数:8被引数:294
S
Shinji Ohno
H 指数:62论文数:565被引数:2.3万
T
Tatsuya Toyama
H 指数:51论文数:319被引数:7,446
K
Keitaro Matsuo
H 指数:115论文数:1,564被引数:5.6万
A
Akiyo Yoshimura
H 指数:20论文数:101被引数:1,693
H
Haruru Kotani
H 指数:19论文数:89被引数:5,984